Cumulative Incidence of Mortality Associated with Cardiovascular-Kidney-Metabolic (CKM) Syndrome

被引:1
作者
Claudel, Sophie E. [1 ]
Schmidt, Insa M. [2 ]
Waikar, Sushrut S. [2 ]
Verma, Ashish [2 ]
机构
[1] Boston Med Ctr, Dept Med, Boston, MA USA
[2] Boston Univ, Chobanian & Avedisian Sch Med, Dept Med, Sect Nephrol, Boston, MA 02215 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2025年
关键词
cardiovascular disease; CKD; diabetes mellitus; epidemiology and outcomes; mortality risk; US ADULTS; OBESITY; EVENTS; STATEMENT; DISEASE; TRENDS;
D O I
10.1681/ASN.0000000637
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Key PointsCardiovascular-kidney-metabolic (CKM) syndrome stages 1-4 were associated with a graded risk of cardiovascular mortality in a nationally representative sample of US adults.Risk was similar between stages 0 and 1, suggesting that stage 1 represents a prime opportunity for prevention and risk mitigation.CKM staging is specific to cardiovascular mortality, given lack of a strong association with either noncardiovascular or cancer mortality.BackgroundIt is imperative to critically evaluate the prognostic implications of cardiovascular-kidney-metabolic (CKM) syndrome staging to inform clinical practice. The primary aims of this study were to define the risk of mortality associated with each CKM syndrome stage and to determine the corresponding restricted mean survival time over a 15-year period.MethodsThis was a longitudinal study of 50,678 community-dwelling US adults aged 20 years and older with baseline data for CKM stage determination participating in the 1999-2018 National Health and Nutrition Examination Survey. CKM stages were defined according to the American Heart Association presidential advisory. Fifteen-year adjusted cumulative incidences of cardiovascular mortality were calculated for each stage from confounder-adjusted survival curves using the G-formula.ResultsOver a median 9.5-year follow-up, 2564 participants experienced cardiovascular death. The 15-year adjusted cumulative incidences of cardiovascular mortality were stage 0, 5.5% (95% confidence interval [CI], 1.8 to 9.3); stage 1, 5.7% (95% CI, 3.2 to 8.2); stage 2, 7.9% (95% CI, 6.8 to 9.1); stage 3, 8.7% (95% CI, 6.7 to 10.8); and stage 4, 15.2% (95% CI, 13.6 to 16.8). The absolute risk difference between CKM stage 4 and stage 0 at 15 years was 9.6% (95% CI, 5.6 to 13.6). The survival difference between CKM stage 0 and stage 4 at 15 years was 8.1 (95% CI, 8.0 to 8.2) months.ConclusionsOur findings reveal a graded risk of cardiovascular mortality associated with higher CKM syndrome stage.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Metabolic syndrome definitions and components in predicting major adverse cardiovascular events after kidney transplantation
    Prasad, G. V. Ramesh
    Huang, Michael
    Silver, Samuel A.
    Al-Lawati, Ali I.
    Rapi, Lindita
    Nash, Michelle M.
    Zaltzman, Jeffrey S.
    TRANSPLANT INTERNATIONAL, 2015, 28 (01) : 79 - 88
  • [42] Metabolic Syndrome Is Not Associated With Increased Mortality or Cardiovascular Risk in Nondiabetic Patients With a New Diagnosis of Coronary Artery Disease
    Petersen, John L.
    Yow, Eric
    AlJaroudi, Wael
    Shaw, Linda K.
    Goyal, Abhinav
    McGuire, Darren K.
    Peterson, Eric D.
    Harrington, Robert A.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2010, 3 (02): : 165 - 172
  • [43] The Impact of the Aryl Hydrocarbon Receptor on Antenatal Chemical Exposure-Induced Cardiovascular-Kidney-Metabolic Programming
    Tain, You-Lin
    Hsu, Chien-Ning
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (09)
  • [44] Association between Chinese visceral adiposity index and cardiovascular events risk in individuals with cardiovascular-kidney-metabolic syndrome stage 0-3: a nationwide cohort study
    Shen, Xiaobo
    Liu, Qi
    Lin, Tianchen
    Zheng, Danna
    He, Qiang
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025, : 2255 - 2269
  • [45] Association of the stress hyperglycemia ratio for all-cause and cardiovascular mortality in population with cardiovascular-kidney-metabolic syndrome stages 0-4: evidence from a large cohort study
    Guo, Fan-Shun
    Dou, Jia-Hao
    Wang, Jun-Xiang
    Guo, Chen
    Wu, Rui-Yun
    Sun, Xue-Lu
    Hu, Yi-Wei
    Wei, Jin
    DIABETOLOGY & METABOLIC SYNDROME, 2025, 17 (01)
  • [46] Human genetics identify convergent signals in mitochondrial LACTB-mediated lipid metabolism in cardiovascular-kidney-metabolic syndrome
    Li, Shen
    Liu, Hongbo
    Hu, Hailong
    Ha, Eunji
    Prasad, Praveena
    Jenkins, Brenita C.
    Das, Ujjalkumar Subhash
    Mukherjee, Sarmistha
    Shishikura, Kyosuke
    Hu, Renming
    Rader, Daniel J.
    Pei, Liming
    Baur, Joseph A.
    Matthews, Megan L.
    FitzGerald, Garret A.
    McReynolds, Melanie R.
    Susztak, Katalin
    CELL METABOLISM, 2025, 37 (01) : 154 - +
  • [47] Cardiovascular-kidney-metabolic syndrome modifies smoking-related risk for cardiovascular diseases: findings from an observational cohort study in UK Biobank
    Xinhui Liu
    Heng Zhang
    Hongkai Li
    Fuzhong Xue
    BMC Public Health, 25 (1)
  • [48] Association between atherogenic index of plasma and future risk of cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide prospective cohort study
    Zheng, Gaoshu
    Jin, Jijie
    Wang, Fei
    Zheng, Qianrong
    Shao, Jiaxin
    Yao, Jiangnan
    Huang, Pan
    Zhou, Hao
    Zhou, Jianghua
    CARDIOVASCULAR DIABETOLOGY, 2025, 24 (01)
  • [49] Maternal Dietary Strategies for Improving Offspring Cardiovascular-Kidney-Metabolic Health: A Scoping Review
    Tain, You-Lin
    Hsu, Chien-Ning
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (18)
  • [50] Association between triglyceride-glucose related indices and all-cause and cardiovascular mortality among the population with cardiovascular-kidney-metabolic syndrome stage 0-3: a cohort study
    Zhang, Peng
    Mo, Degang
    Zeng, Wenhua
    Dai, Hongyan
    CARDIOVASCULAR DIABETOLOGY, 2025, 24 (01)